Unknown

Dataset Information

0

Atezolizumab for the treatment of non-small cell lung cancer.


ABSTRACT: INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high neoantigen creation and sensitization to immune recognition. Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1). Areas covered: This drug profile article covers the basics of the cancer-immunity cycle and reviews some aspects of innate and adaptive immunology. We discuss the discovery of PD-L1 and PD-L2 while highlight the potential differences in targeting PD-L1 versus PD-1. In addition, we briefly summarized the available pre-clinical and clinical data of atezolizumab use in NSCLC. A special section covers the challenges of PD-L1 immunohistochemistry assay. Expert commentary: PD-1:PD-L1 blockade has taken the lead in the immunotherapeutics field and represents the backbone of developing combination immunotherapies. Atezolizumab represents a step forward in the treatment of advanced NSCLC, nonetheless PD1:PD-L1 blockade in early-stage lung cancer is still a matter of debate.

SUBMITTER: Santini FC 

PROVIDER: S-EPMC6089509 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Atezolizumab for the treatment of non-small cell lung cancer.

Santini Fernando C FC   Rudin Charles M CM  

Expert review of clinical pharmacology 20170727 9


<h4>Introduction</h4>The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high neoantigen creation and sensitization to immune recognition. Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1). Areas covered: This drug profi  ...[more]

Similar Datasets

| S-EPMC6186653 | biostudies-literature
| S-EPMC6137949 | biostudies-literature
| S-EPMC5516873 | biostudies-literature
| S-EPMC6066722 | biostudies-literature
| S-EPMC8499805 | biostudies-literature
| S-EPMC8212861 | biostudies-literature
| S-EPMC7396979 | biostudies-literature
| S-EPMC10453652 | biostudies-literature
| S-EPMC10163154 | biostudies-literature
| S-EPMC9746048 | biostudies-literature